Presented at ASH 2025: EPCORE CLL-1 trial on epcoritamab monotherapy for Richter transformation

ASH 2025 Preview - Expert Roundtable

Arnon Kater and Sabina Kersting on the HOVON 158/NEXT STEP phase 2 trial testing a new first-line treatment regimen for chronic lymphocytic leukaemia

Ruben Mesa on ropeginterferon alfa-2b for hydroxyurea-intolerant or hydroxyurea-refractory essential thrombocythaemia

A panel of the authors on our Lancet Haematology-Lancet Regional Health Western Pacific Series on mature T-cell and natural killer-cell lymphomas

Lan-Lan Smith, Cheryl Lai, and Daniela Marín discuss the EHA, ICML, and ISTH conferences

Paolo Strati on off-the-shelf induced pluripotent stem-cell-derived natural killer-cell therapy for patients with relapsed or refractory B-cell lymphoma

A panel of the authors on our Adverse Events Series on adverse event reporting in haematological malignancies

Michael Northend on early rituximab monotherapy versus watchful waiting for advanced stage, asymptomatic, low tumour burden follicular lymphoma

Joanne Verweij and Romy Pothof on fetal and neonatal alloimmune thrombocytopenia

Helene Schoemans, Elke Stienissen, and Kathy Goris on a consulting a patient advisory board to understand unmet needs of patients with GVHD in Europe

Dawn Swan on air pollution and venous thromboembolism

Leslie Skeith on low-dose aspirin for postpartum venous thromboembolism prophylaxis

Neema Mayor and Caitlin Farrow on impact of patient ethnicity on haematopoeietic cell transplantation outcome in the United Kingdom

Lancet Haematology 10 year anniversary - meet the editors

Matteo Della Porta on the phase 3 COMMANDS trial examining luspatercept versus epoetin alfa in patients with lower-risk myleodysplastic syndrome

Kim Linton on follicular lymphoma

Judy Truong on ferritin reference levels and iron deficiency

Johannes Schetelig on remission induction versus immediate allogeneic HSCT for patients with AML

Banu Aygun on sickle cell anaemia